Innoviva, Inc. (INVA) FY2025 10-K Annual Report
Innoviva, Inc. (INVA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Innoviva, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: diversified biopharmaceutical company with royalties portfolio plus critical care and infectious disease operating platform (Innoviva Specialty Therapeutics)
- • New products launched: XACDURO® (2023), ZEVTERA® (Q3 2025), and FDA approval of NUZOLVENCE® (Dec 2025) for infectious diseases
- • Strategic shift: transformation from pure-play royalty business to diversified biopharma with fast-growing, differentiated operating platform
- • Notable metric: XACDURO® Phase 3 ATTACK trial showed 19.0% mortality vs 32.3% for colistin; approved in US (2023) and China (2024)
- • Unusual fact: XACDURO® named preferred treatment for carbapenem-resistant Acinetobacter baumannii in 2024 IDSA guidelines
Management Discussion & Analysis
- • Revenue details and YoY change not disclosed in provided MD&A excerpt
- • Profitability or margin data not included in provided text
- • Segment performance metrics not available in excerpt
- • Cash flow, buybacks, dividends, capex information not provided
- • Forward-looking statements referenced with risks, no specific guidance or outlook given
Risk Factors
- • FDA approval of NUZOLVENCE® in Dec 2025, with commercialization planned in H2 2026, regulatory risk around market launch and adoption timing
- • Pricing pressures in U.S. caused 2% decline in royalty revenue to $236.5M in 2025, signaling macroeconomic risk on revenue from GSK royalty portfolio
- • Supply vulnerability from Zai Lab interim supply agreement for XACDURO® ex-U.S. sales, accounting for significant 218% YoY increase to $40.9M
- • Competition risk from established respiratory products RELVAR®/BREO® and ANORO® ELLIPTA® partnered with GSK, with royalties tiered 15% up to $3B sales then 5%
- • $300M capital locked in ISP Fund with Sarissa Capital as advisor and withdrawal restrictions, creating financial liquidity and concentration risk until April 2026 distributions
Innoviva, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$411M
▲ +14.7% YoY
Net Income
$271M
▲ +1059.2% YoY
Gross Margin
74.8%
▼ -778bp YoY
Operating Margin
39.8%
▼ -671bp YoY
Net Margin
65.9%
▲ +5940bp YoY
ROE
23.1%
▲ +1974bp YoY
Total Assets
$1.6B
▲ +25.7% YoY
EPS (Diluted)
$3.30
▲ +816.7% YoY
Operating Cash Flow
$197M
▲ +4.4% YoY
Source: XBRL data from Innoviva, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Innoviva, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.